Sven Mahner

Summary

Country: Germany

Publications

  1. ncbi TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    BMC Cancer 10:139. 2010
  2. ncbi Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials
    S Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Eur J Cancer 49:142-9. 2013
  3. ncbi A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Cancer Res Clin Oncol 138:1413-9. 2012
  4. ncbi Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction
    Sven Mahner
    Department of Gynecology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany
    Anticancer Res 29:2817-21. 2009
  5. ncbi Serum carbonic anhydrase IX during first-line therapy of ovarian cancer
    Linn Woelber
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Gynecol Oncol 117:183-8. 2010
  6. ncbi Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer
    Lilli Kock
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Int J Gynecol Cancer 21:141-8. 2011
  7. ncbi Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Ann Surg Oncol 18:3811-8. 2011
  8. ncbi Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome
    Isabell D Witzel
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    J Cancer Res Clin Oncol 136:1709-18. 2010
  9. ncbi Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients
    Maike Ihnen
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    BMC Cancer 12:140. 2012
  10. ncbi Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment
    Linn Woelber
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Int J Gynecol Cancer 22:503-8. 2012

Collaborators

Detail Information

Publications24

  1. ncbi TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    BMC Cancer 10:139. 2010
    ..The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear...
  2. ncbi Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials
    S Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Eur J Cancer 49:142-9. 2013
    ..The impact of the time interval between surgery and initiation of chemotherapy for clinical outcome has not been clarified yet...
  3. ncbi A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis
    Sven Mahner
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    J Cancer Res Clin Oncol 138:1413-9. 2012
    ....
  4. ncbi Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction
    Sven Mahner
    Department of Gynecology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany
    Anticancer Res 29:2817-21. 2009
    ..Routine measurement of the tumor marker CA-125 is often used in the follow-up management. However, the role of preoperative CA-125 as a prognostic factor before secondary cytoreduction of relapsed ovarian cancer has not been determined...
  5. ncbi Serum carbonic anhydrase IX during first-line therapy of ovarian cancer
    Linn Woelber
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Gynecol Oncol 117:183-8. 2010
    ..It is overexpressed in a variety of tumors including ovarian cancer. To evaluate the potential prognostic and predictive role of serum CAIX for therapy response in ovarian cancer, we analyzed longitudinal serum samples...
  6. ncbi Serum carbonic anhydrase IX and its prognostic relevance in vulvar cancer
    Lilli Kock
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Int J Gynecol Cancer 21:141-8. 2011
    ..We therefore determined CAIX serum concentration and its prognostic relevance in correlation to intratumoral CAIX expression in patients with primary vulvar cancer...
  7. ncbi Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Ann Surg Oncol 18:3811-8. 2011
    ..A tumor-free resection margin of at least 8 mm is considered state of the art in vulvar cancer. This standard is based on small and heterogeneous patient cohorts, and its implementation can result in mutilation...
  8. ncbi Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome
    Isabell D Witzel
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    J Cancer Res Clin Oncol 136:1709-18. 2010
    ..To investigate the correlation between RNA and protein levels, we assessed HER2, uPA and PAI-1 in patients with breast cancer. In addition, we evaluated the influence of these factors on patient outcome...
  9. ncbi Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients
    Maike Ihnen
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    BMC Cancer 12:140. 2012
    ..In some cancers ALCAM has a prognostic value or is predictive for the benefit of therapeutic interventions. To date there are no data on the role of ALCAM in cervical cancer available...
  10. ncbi Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment
    Linn Woelber
    Department of Gynecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Int J Gynecol Cancer 22:503-8. 2012
    ..However, information regarding the impact of the number of positive nodes in vulvar cancer is inconsistent, and so are recommendations when to apply adjuvant radiotherapy...
  11. ncbi Prognostic factors for complete debulking in first- and second-line ovarian cancer
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Ludwig Erhard Strasse 100, Wiesbaden, Germany
    Int J Gynecol Cancer 19:S14-7. 2009
    ..Surgery is a mainstay of therapy in ovarian cancer. Are there any actual changes in the definitions and goals of surgery?..
  12. ncbi Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Centre Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    BMC Cancer 11:12. 2011
    ..The protein is overexpressed in a variety of tumors and potentially associated with negative outcome. This study was designed to investigate the prognostic role of CAIX in serum and tumor tissue of patients with primary cervical cancer...
  13. ncbi Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Strasse 100, D 65199 Wiesbaden, Germany
    Expert Rev Anticancer Ther 10:81-8. 2010
    ..Actual treatment options and strategies in recurrent ovarian cancer will also be discussed. Furthermore, this review focuses on new drugs in the treatment of primary and recurrent ovarian cancer...
  14. ncbi Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer
    Dina Mury
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
    J Cancer Res Clin Oncol 137:1131-7. 2011
    ..To stratify patients for optimal therapy, prognostic and predictive factors are needed. We examined the role of pre- and postoperative CA-125 in this context...
  15. ncbi Management of patients with vulvar cancer: a perspective review according to tumour stage
    Linn Woelber
    Department of Gynaecology and Gynaecologic Oncology, University Medical Centre Hamburg Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany
    Ther Adv Med Oncol 5:183-92. 2013
    ..This review therefore puts different recommendations of clinical management in context and highlights the need for future trials...
  16. ncbi Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer
    Linn Woelber
    Department of Gynaecology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Anticancer Res 29:545-52. 2009
    ..The aim of this study was to determine prognostic variables for recurrence and survival and to identify patterns of recurrence in patients with vulvar cancer...
  17. ncbi Clinical management of primary vulvar cancer
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, D 20246 Hamburg, Germany
    Eur J Cancer 47:2315-21. 2011
    ..This article discusses the current literature to elaborate recommendations for the management of primary vulvar cancer in clinical routine...
  18. ncbi Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases
    Matthias Choschzick
    Institute of Pathology, University Medical Centre Hamburg Eppendorf, Hamburg, Germany
    Virchows Arch 456:483-90. 2010
    ..Our data support the potential therapeutic benefit of newly developed targeting antibodies in advanced vulvar cancer...
  19. ncbi Secondary sentinel node biopsy after previous excision of the primary tumor in squamous cell carcinoma of the vulva
    Linn Woelber
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Ann Surg Oncol 20:1701-6. 2013
    ..It has been proven to be a safe alternative in early-stage disease. Feasibility and safety of the procedure after previous vulvar surgery remain unclear...
  20. ncbi Assessment of cervical intraepithelial neoplasia (CIN) with colposcopic biopsy and efficacy of loop electrosurgical excision procedure (LEEP)
    Nina Duesing
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany
    Arch Gynecol Obstet 286:1549-54. 2012
    ..The present study analyses the accuracy of preoperative assessment of CIN with cytology plus colposcopic biopsy and assesses the efficacy of LEEP for the treatment of CIN...
  21. ncbi Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Klinik, Wiesbaden, Germany
    Int J Gynecol Cancer 21:289-95. 2011
    ..The DESKTOP II trial was planned to verify this hypothesis prospectively in a multicenter setting...
  22. ncbi Role of cytoreductive surgery in recurrent ovarian cancer
    Philipp Harter
    Department of Gynecology and Gynecologic Oncology, HSK, Dr Horst Schmidt Klinik, Ludwig Erhard Str 100, D 65199 Wiesbaden, Germany
    Expert Rev Anticancer Ther 9:917-22. 2009
    ..The surgical end point in recurrent ovarian cancer should be complete resection. Predictive factors could help identify patients in whom complete resection is possible...
  23. ncbi Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD
    Radoslav Chekerov
    Department of Gynecology, European Competence Centre for Ovarian Cancer, Charite University Hospital, Campus Virchow, Berlin, Germany
    Int J Gynecol Cancer 23:268-75. 2013
    ..Here we present the main pathologic, surgical, and chemotherapy characteristics of the OVCAD patient cohort...
  24. ncbi Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines
    Sibyll Hein
    Department of Gynecology and Gynecologic Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
    Oncol Rep 22:177-83. 2009
    ..No correlation with the proliferative and invasive potential of ovarian cancer cell lines could be found...